US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

KraneShares MSCI All China Health Care Index ETF

18.50

-0.6100-3.19%

Volume:26.77K

Turnover:497.45K

Market Cap:107.32M

PE:- -

High:18.69

Open:18.62

Low:18.50

Close:19.11

52wk High:21.88

52wk Low:14.38

Shares:5.80M

Float Shares:5.80M

Volume Ratio:0.80

T/O Rate:0.46%

Dividend:0.71

Dividend Rate:3.86%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

CSPC Pharmaceutical Starts Phase 2 Trial of Hypertension Drug

MT Newswires Live

CSPC Pharma's CRB-701 (SYS 6002) Gets FDA Nod for Phase 2 Trial in Oropharyngeal Cancer

CSPC Says FDA Clears Crb-701 Pivotal Trial in Second-line Oropharyngeal Cancer

CSPC Pharmaceutical - Crb-701 Receives FDA Clearance for Registrational Trial in Second-Line Oropharyngeal Cancer

THOMSON REUTERS

CSPC Pharmaceutical Group Stock Rallies 3.2% in Hong Kong, Outperforms Competitors

Citi Reaffirms Buy Rating on CSPC Pharma, Sets Price Target at HK$11.50

China's Biotechnology Success Meets Increasing US Scrutiny, Analytics Firm Says

MT Newswires Live

WuXi Biologics Added to FTSE4Good Index Series for Sixth Straight Year

Citi: CSPC Pharma's (01093) Interim Profit Alert Far Exceeds Expectations, 'Buy' Rating Reaffirmed

China's CSPC Pharmaceutical Rises on Robust H1 Earnings Forecast

CSPC Pharma's Depression Drug Meets Primary Endpoint in Phase 3 Trial

MT Newswires Live

Akeso Doses First Patient in Phase Ib/II NSCLC Trial of HER3 ADC Ak138d1 with Ivonescimab

CSPC Pharma's Sirolimus Drug Application Accepted in China

MT Newswires Live

Hong Kong Stock Market Preview: Disease Prevention 15th Five-Year Plan Issued, SK Hynix Breaches IPO Price on Wall Street

Cspc Pharmaceutical Says Phase III Trial of Ha1406 Meets Primary Endpoint

CSPC PHARMA's Injectable Sirolimus (Albumin-Bound) New Drug Application Accepted by China's NMPA

CSPC Says China NMPA Accepts Sirolimus Albumin-bound Injection Filing, Grants Priority Review

CSPC Pharmaceutical - Nmpa Accepts New Drug Application for Sirolimus for Injection (Albumin-Bound)

THOMSON REUTERS

CSPC Pharmaceutical - Phase Iii Trial of Ha1406 for Depression Meets Primary Endpoint with Statistical Significance

THOMSON REUTERS

CSPC PHARMA (01093) Issues Positive Profit Alert, Expects Significant Interim Net Profit Growth to Around RMB 5.9-6.2 Billion

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/KURE/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KURE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KURE\",,,,,undefined,":{"symbol":"KURE","market":"US","secType":"STK","nameCN":"KraneShares MSCI All China Health Care Index ETF","latestPrice":18.5,"timestamp":1787590841741,"preClose":19.11,"halted":0,"volume":26773,"delay":0,"changeRate":-0.031920460491889034,"floatShares":5800979,"shares":5800979,"eps":0,"marketStatus":"Trading","change":-0.61,"latestTime":"08-24 13:01:38 EDT","open":18.615,"high":18.69,"low":18.5,"amount":497448.31037900003,"amplitude":0.009942,"askPrice":18.72,"askSize":100,"bidPrice":18.38,"bidSize":400,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787601600000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":19.11,"sharesOutstanding":4750002,"nav":18.99,"aum":110160584.96,"dividendRate":0.038638,"bidAskSpread":0.003071,"preHourTrading":{"tag":"盘前","latestPrice":18.5,"preClose":19.11,"latestTime":"07:56 EDT","volume":54,"amount":998.020008,"timestamp":1787572607542,"change":-0.61,"changeRate":-0.03192,"amplitude":0.005128},"postHourTrading":{"tag":"盘后","latestPrice":19.33,"preClose":19.11,"latestTime":"19:13 EDT","volume":111,"amount":2143.44,"timestamp":1787353996933,"change":0.22,"changeRate":0.011512,"amplitude":0.011512},"volumeRatio":0.800154,"impliedVol":0.3186,"impliedVolPercentile":0.6574},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KURE\",,,,,undefined,":{"symbol":"KURE","floatShares":5800979,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.800154,"shares":5800979,"dividePrice":0.7148,"high":18.69,"amplitude":0.009942,"preClose":19.11,"low":18.5,"week52Low":14.3797,"pbRate":"--","week52High":21.875,"institutionHeld":0,"latestPrice":18.5,"committee":0.6,"eps":0,"divideRate":0.038638,"volume":26773,"delay":0,"ttmEps":0,"open":18.615,"prevYearClose":17.04,"prevWeekClose":19.11,"prevMonthClose":17.28,"prevQuarterClose":15.747,"fiveDayClose":18.6,"twentyDayClose":17.3752,"sixtyDayClose":15.66},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KURE\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"KURE","amount":0.714689,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"KraneShares MSCI All China Health Care Index ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-23","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-23"},{"date":"2024-12-17","symbol":"KURE","amount":0.18361,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"KraneShares MSCI All China Health Care Index ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-18","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-18"},{"date":"2023-12-18","symbol":"KURE","amount":0.112844,"announcedDate":"2023-12-15","type":"dividend","market":"US","newRecordDate":"2023-12-19","defaultRemindTime":1702909800000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2023-12-20","payableDate":"2023-12-19","currency":"USD","dateTimestamp":1702875600000,"payDate":"2023-12-20"},{"market":"US","date":"2022-12-28","symbol":"KURE","amount":0.010399,"defaultRemindTime":1672237800000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2022-12-30","payableDate":"2022-12-29","currency":"USD","type":"dividend","dateTimestamp":1672203600000},{"market":"US","date":"2021-12-29","symbol":"KURE","amount":4.053448,"defaultRemindTime":1640788200000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2021-12-31","payableDate":"2021-12-30","currency":"USD","type":"dividend","dateTimestamp":1640754000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KURE\",market:\"US\",,,undefined,":[{"executeDate":"2018-12-26","recordDate":"2018-12-27","paymentDate":"2018-12-28","value":0.039344,"currency":"USD"},{"executeDate":"2019-12-27","recordDate":"2019-12-30","paymentDate":"2019-12-31","value":0.057325,"currency":"USD"},{"executeDate":"2020-12-29","recordDate":"2020-12-30","paymentDate":"2020-12-31","value":0.000109,"currency":"USD"},{"executeDate":"2021-12-29","recordDate":"2021-12-30","paymentDate":"2021-12-31","value":4.053448,"currency":"USD"},{"executeDate":"2022-12-28","recordDate":"2022-12-29","paymentDate":"2022-12-30","value":0.010399,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KURE\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KURE\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2655849748","title":"CSPC Pharmaceutical Starts Phase 2 Trial of Hypertension Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2655849748","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655849748?lang=en_us&edition=fundamental","pubTime":"2026-07-30 10:44","pubTimestamp":1785379449,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical (HKG:1093) has initiated the first China study site for a Phase 2 clinical trial of SYH2062 injection for the treatment of adult essential hypertension, according to a Wednesday Ho","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["KURE","IE0008368742.USD","IE00B543WZ88.USD","LU0140636845.USD","LU1328277881.USD","IE00BZ08YS42.EUR","LU0326950275.SGD","LU0501845795.SGD","IE00BZ08YT58.USD","LU1813983027.USD","SG9999004220.SGD","LU1951186391.HKD","LU0314109678.HKD","LU0880133367.SGD","LU2039709279.SGD","BK1515","LU1226288170.HKD","BK1191","LU1226288253.USD","01093","IE00B5MMRT66.SGD","LU1152091168.USD","LU1993786604.SGD","LU1226287875.USD","LU1807302812.USD","LU1226287792.SGD","HK0000165453.HKD","IE00B031HY20.USD","LU0315179316.USD","LU0072913022.USD","IE00BZ08YR35.GBP","LU1152091754.HKD","BK1521","LU1226287529.USD","LU0067412154.USD","IE0008369823.USD","LU1008478684.HKD","LU1960683339.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128841602","title":"CSPC Pharma's CRB-701 (SYS 6002) Gets FDA Nod for Phase 2 Trial in Oropharyngeal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=1128841602","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128841602?lang=en_us&edition=fundamental","pubTime":"2026-07-29 20:42","pubTimestamp":1785328921,"startTime":"0","endTime":"0","summary":"CSPC PHARMA (01093) has announced that its licensed candidate, CRB-701 (SYS 6002), developed by Corbus Pharmaceuticals, Inc., has received U.S. FDA approval to initiate a registration-directed...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1521","IE00BZ08YR35.GBP","KURE","LU1152091754.HKD","BK4585","LU1008478684.HKD","LU1226287529.USD","LU1993786604.SGD","SG9999004220.SGD","LU1226287792.SGD","LU1226288253.USD","LABU","IE00B5MMRT66.SGD","IE00BZ08YS42.EUR","LU1807302812.USD","IE0008368742.USD","LU0072913022.USD","LU1226287875.USD","LU1951186391.HKD","BK4588","LU2039709279.SGD","IBBJ","LU1813983027.USD","LU0315179316.USD","BMED","LU0140636845.USD","LU0880133367.SGD","LU1960683339.HKD","LU0314109678.HKD","LU1226288170.HKD","LU0501845795.SGD","LU1152091168.USD","IE00BZ08YT58.USD","PSYK","IE00B031HY20.USD","LU0067412154.USD","IBBQ","LU0326950275.SGD","01093","HK0000165453.HKD","MDTX","LU1328277881.USD","IE00B543WZ88.USD","IE0008369823.USD","BK1515","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655898309","title":"CSPC Says FDA Clears Crb-701 Pivotal Trial in Second-line Oropharyngeal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2655898309","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655898309?lang=en_us&edition=fundamental","pubTime":"2026-07-29 20:34","pubTimestamp":1785328493,"startTime":"0","endTime":"0","summary":"CSPC says FDA clears CRB-701 pivotal trial in second-line oropharyngeal cancerCSPC said the FDA cleared Corbus’s CRB-701 (SYS 6002) to start TEMPO-1, a registrational trial in second-line oropharyngea","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nNDL5kgpQ6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1226287792.SGD","LU1807302812.USD","BK1191","IE00BZ08YS42.EUR","LU1960683339.HKD","LU1226288170.HKD","01093","IE0008368742.USD","LU0067412154.USD","KURE","LU0140636845.USD","LU0501845795.SGD","LU1226287875.USD","IE00B031HY20.USD","LU1152091754.HKD","LU1226288253.USD","IE00B543WZ88.USD","IE00BZ08YR35.GBP","LU2039709279.SGD","BK1515","LU0072913022.USD","IE00B5MMRT66.SGD","LU1008478684.HKD","LU1152091168.USD","SG9999004220.SGD","LU0314109678.HKD","HK0000165453.HKD","BK1521","LU1226287529.USD","LU1993786604.SGD","IE0008369823.USD","LU0326950275.SGD","LU1951186391.HKD","LU1328277881.USD","LU0315179316.USD","LU1813983027.USD","IE00BZ08YT58.USD","LU0880133367.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655898318","title":"CSPC Pharmaceutical - Crb-701 Receives FDA Clearance for Registrational Trial in Second-Line Oropharyngeal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2655898318","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655898318?lang=en_us&edition=fundamental","pubTime":"2026-07-29 20:33","pubTimestamp":1785328390,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nFWN43V1S5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1226287875.USD","LU0072913022.USD","IE00BZ08YR35.GBP","LU0314109678.HKD","KURE","LU1951186391.HKD","LU0501845795.SGD","BK1521","LU1226287529.USD","IE00B031HY20.USD","LU1008478684.HKD","LU1813983027.USD","LU1807302812.USD","LU2039709279.SGD","LU1152091754.HKD","LU0880133367.SGD","01093","LU0315179316.USD","LU1226288170.HKD","LU0067412154.USD","BK1515","LU1993786604.SGD","IE00BZ08YT58.USD","IE0008369823.USD","BK1191","LU1226288253.USD","IE00BZ08YS42.EUR","LU1960683339.HKD","IE00B543WZ88.USD","IE0008368742.USD","LU1152091168.USD","HK0000165453.HKD","IE00B5MMRT66.SGD","LU0326950275.SGD","LU0140636845.USD","SG9999004220.SGD","LU1226287792.SGD","LU1328277881.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655125850","title":"CSPC Pharmaceutical Group Stock Rallies 3.2% in Hong Kong, Outperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2655125850","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655125850?lang=en_us&edition=fundamental","pubTime":"2026-07-29 16:32","pubTimestamp":1785313920,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of CSPC Pharmaceutical Group Ltd. rose 3.2% to 8.76 Hong Kong dollars on what proved to be an all-around great trading session for the Hong Kong stock market, with the Hang Seng Index rising 2.0% to 25807.92.This was the stock's second consecutive day of gains.CSPC Pharmaceutical Group Ltd. closed 25% short of its 52-week high of HK$11.63, which the company achieved Sept. 9.The stock outperformed some of its competitors, as Sino Biopharmaceutical Ltd. rose 2.8%, SSY Group Ltd. rose 1.7%, and United Laboratories International Holdings Ltd. rose 2.2%.Trading volume totaled 93.9 million shares, compared to the 50-day average of 106.8 million shares.Data source: Dow Jones Market Data, FactSet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999004220.SGD","IE00BZ08YT58.USD","LU1328277881.USD","LU1807302812.USD","LU1226287792.SGD","LU1226288170.HKD","LU1951186391.HKD","LU0501845795.SGD","LU0072913022.USD","LU1960683339.HKD","LU1993786604.SGD","LU0140636845.USD","LU1226288253.USD","BK1191","LU1813983027.USD","LU0326950275.SGD","IE00B5MMRT66.SGD","LU2039709279.SGD","BK1521","KURE","LU1152091168.USD","LU1152091754.HKD","LU1008478684.HKD","LU0315179316.USD","IE0008368742.USD","LU1226287875.USD","LU0314109678.HKD","LU0880133367.SGD","LU0067412154.USD","01093","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","IE0008369823.USD","BK1515","HK0000165453.HKD","IE00B543WZ88.USD","LU1226287529.USD","IE00B031HY20.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117361505","title":"Citi Reaffirms Buy Rating on CSPC Pharma, Sets Price Target at HK$11.50","url":"https://stock-news.laohu8.com/highlight/detail?id=1117361505","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117361505?lang=en_us&edition=fundamental","pubTime":"2026-07-29 12:52","pubTimestamp":1785300721,"startTime":"0","endTime":"0","summary":"Citi recently released a research report stating that CSPC PHARMA (01093) has issued a profit alert. The company expects its net profit for the first half of the year to range between 5.9 billion and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FTXO","LU1008478684.HKD","EWH","LU0106831901.USD","LU0072913022.USD","LU1951186391.HKD","LU0310800965.SGD","IE00BSNM7G36.USD","LU2456880835.USD","LU0880133367.SGD","C","LU0314109678.HKD","LU1226288170.HKD","IE0008369823.USD","LU0098860793.USD","LU1267930227.SGD","BK4566","BK1515","KURE","LU1074936037.SGD","LU0052756011.USD","LU2417539215.USD","LU1993786604.SGD","BK4207","IE00B5MMRT66.SGD","LU1244550494.USD","LU1807302812.USD","LU0130102774.USD","LU1226287875.USD","LU1960683339.HKD","LU1244550577.SGD","LU0477156953.USD","LU0072461881.USD","LU1328277881.USD","IE00B543WZ88.USD","BK1521","IE00BZ08YR35.GBP","LU1162221912.USD","LU2125154778.USD","LU0170899867.USD","BK4585","LU1668664300.SGD","LU1226287529.USD","SG9999004220.SGD","LU1791807156.HKD","BK4504","IE00BZ08YS42.EUR","IE0008368742.USD","LU0128525689.USD","BK4559","LU0162691827.USD","LU0315179316.USD","LU0203345920.USD","LU0320765646.SGD","LU2462157665.USD","LU0648001328.SGD","LU2236285917.USD","TFNS","LU0501845795.SGD","LU1152091168.USD","IE00BZ08YT58.USD","LU0980610538.SGD","LU0130517989.USD","IE00B031HY20.USD","LU0326950275.SGD","HK0000165453.HKD","LU1244550221.USD","LU1152091754.HKD","LU1201861249.SGD","LU0314106906.USD","IYF","LU1506573853.SGD","LU1226287792.SGD","LU1226288253.USD","BK4588","LU2039709279.SGD","LU1813983027.USD","LU2125154935.USD","LU0140636845.USD","LU2360032135.SGD","LU0203347892.USD","LU0067412154.USD","01093","BK4534","LU1366192091.USD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655853679","title":"China's Biotechnology Success Meets Increasing US Scrutiny, Analytics Firm Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2655853679","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655853679?lang=en_us&edition=fundamental","pubTime":"2026-07-29 12:19","pubTimestamp":1785298770,"startTime":"0","endTime":"0","summary":"China's rise as a global biotechnology innovation hub has worried the U.S., driving Washington to scrutinize the country's competitiveness and technological leadership rather than scientific advances alone, analytics firm GlobalData said in a Tuesday press release.The implications of China's emergence extends \"beyond healthcare innovation to include pharmaceutical supply-chain resilience, economic competitiveness, and national security,\" GlobalData healthcare analyst Edita Hamzic said.GlobalData cited Akeso's  presentation of its ivonescimab therapy at the American Society of Clinical Oncology as the first drug developed from a China-only clinical trial for non-small cell lung cancer patients as a display of China's scientific progress.It also cited Wuxi AppTec's  inclusion in the U.S. Department of Defense's Section 1260H list of \"Chinese military companies\" that could affect its eligilibity for future U.S. governemnt contracts.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1576","BK1141","IE00B5MMRT66.SGD","LU1046422090.SGD","LU1961090484.USD","LU0456842615.SGD","LU2045819591.USD","LU0320764599.SGD","LU2488822045.USD","LU1794554557.SGD","LU0540923850.HKD","LU0348827113.USD","BK1583","02359","LU0561508036.HKD","LU1808992512.USD","LU2476274308.USD","LU0348767384.USD","09926","LU2125910500.SGD","LU0611395673.USD","LU0417516902.SGD","LU1770034418.SGD","LU2242644610.SGD","LU1251922891.USD","603259","IE00B543WZ88.USD","BK1161","LU0348784397.USD","LU0417516738.SGD","LU2495084118.USD","LU0348825331.USD","LU2399975544.HKD","LU0417516571.SGD","LU2476274720.SGD","KURE","LU1969619763.USD","LU2778985437.USD","LU2328871848.SGD","IE00BPRC5H50.USD","BK0216","LU0708995583.HKD","LU0052750758.USD","LU1720050803.USD","LU1997244956.HKD","LU0348766576.USD","LU1997245094.SGD","LU1979443071.USD","LU0348735423.USD","LU0348783233.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655837089","title":"WuXi Biologics Added to FTSE4Good Index Series for Sixth Straight Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2655837089","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655837089?lang=en_us&edition=fundamental","pubTime":"2026-07-29 10:28","pubTimestamp":1785292137,"startTime":"0","endTime":"0","summary":"WuXi Biologics added to FTSE4Good Index Series for sixth straight yearWuXi Biologics added to the FTSE4Good Index Series for a sixth straight year.Inclusion cited strong ESG performance, ranking in th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nNDL4MjZxt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269","LU3063872942.SGD","LU0708995583.HKD","LU1242518931.SGD","LU0516423174.USD","BK1141","LU0052750758.USD","LU0327786744.USD","LU0516423091.SGD","LU2039709279.SGD","LU0572944931.SGD","SG9999002463.SGD","LU0979878070.USD","LU0823426480.USD","LU0516422440.USD","LU1688375341.USD","LU1720050803.USD","LU0307460666.USD","LU0359201612.USD","LU0456827905.SGD","LU0819121731.USD","LU0588546209.SGD","LU0516422366.SGD","LU1880383366.USD","LU1794554557.SGD","BK1610","BK1576","SG9999002562.SGD","BK1589","LU0326950275.SGD","LU0417516738.SGD","LU0039217434.USD","LU1242518857.USD","LU0456846285.SGD","LU0856984785.SGD","LU0348735423.USD","LU0823426308.USD","LU0140636845.USD","LU0181495838.USD","LU0417516902.SGD","KURE","LU0051755006.USD","LU0359202008.SGD","LU0348825331.USD","LU0043850808.USD","LU0320764599.SGD","BK1521","IE00B0JY6N72.USD","LU0516422952.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121995144","title":"Citi: CSPC Pharma's (01093) Interim Profit Alert Far Exceeds Expectations, 'Buy' Rating Reaffirmed","url":"https://stock-news.laohu8.com/highlight/detail?id=1121995144","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121995144?lang=en_us&edition=fundamental","pubTime":"2026-07-28 17:22","pubTimestamp":1785230563,"startTime":"0","endTime":"0","summary":"Citi has released a research report stating that CSPC Pharma (01093) issued a profit alert, forecasting its first-half net profit to range between 5.9 billion and 6.2 billion RMB. This compares to...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1951186391.HKD","LU0067412154.USD","HK0000165453.HKD","01093","IE00BZ08YS42.EUR","LU2039709279.SGD","LU1162221912.USD","LU0310800965.SGD","LU0203347892.USD","BK4566","IE0008369823.USD","LU1226288170.HKD","LU1152091168.USD","LU0162691827.USD","LU2462157665.USD","LU0072461881.USD","LU0128525689.USD","LU1328277881.USD","LU1152091754.HKD","LU0314106906.USD","BK4504","BK1515","LU1244550577.SGD","LU2125154935.USD","LU0326950275.SGD","LU0477156953.USD","LU0072913022.USD","LU0501845795.SGD","LU2456880835.USD","LU1226287792.SGD","IE00B5MMRT66.SGD","LU1807302812.USD","BK1521","IE00BSNM7G36.USD","LU1668664300.SGD","BK4559","LU0130517989.USD","LU0980610538.SGD","IYF","LU0648001328.SGD","LU1226287875.USD","LU0130102774.USD","LU1960683339.HKD","FTXO","LU0106831901.USD","IE00B031HY20.USD","KURE","LU0320765646.SGD","BK4207","LU0098860793.USD","LU1267930227.SGD","IE0008368742.USD","LU0314109678.HKD","LU1226287529.USD","LU1244550494.USD","LU1074936037.SGD","LU1226288253.USD","LU0315179316.USD","LU1244550221.USD","LU1201861249.SGD","BK4588","LU1791807156.HKD","LU2360032135.SGD","LU2125154778.USD","LU1506573853.SGD","C","LU0170899867.USD","LU0140636845.USD","LU1366192091.USD","LU2417539215.USD","TFNS","BK4534","LU1008478684.HKD","BK1191","BK4585","LU1993786604.SGD","LU0880133367.SGD","LU0052756011.USD","LU1813983027.USD","IE00B543WZ88.USD","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","LU2236285917.USD","LU0203345920.USD","SG9999004220.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654027778","title":"China's CSPC Pharmaceutical Rises on Robust H1 Earnings Forecast","url":"https://stock-news.laohu8.com/highlight/detail?id=2654027778","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654027778?lang=en_us&edition=fundamental","pubTime":"2026-07-28 11:18","pubTimestamp":1785208711,"startTime":"0","endTime":"0","summary":"BUZZ-China's CSPC Pharmaceutical rises on robust H1 earnings forecast** Shares of CSPC Pharmaceutical Group1093.HKrise 4.2% to HK$8.65, on course for their biggest one-day pct gain since July 20** The","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nL1N43U036:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1226288170.HKD","LU1226288253.USD","LU1226287875.USD","LU1993786604.SGD","IE00B031HY20.USD","LU1813983027.USD","BK1521","HK0000165453.HKD","LU0072913022.USD","LU2039709279.SGD","BK1515","LU0315179316.USD","LU0880133367.SGD","LU0140636845.USD","IE0008368742.USD","IE00BZ08YR35.GBP","LU1226287792.SGD","LU1951186391.HKD","LU1152091754.HKD","IE00BZ08YT58.USD","01093","LU0314109678.HKD","LU0067412154.USD","SG9999004220.SGD","IE00BZ08YS42.EUR","IE0008369823.USD","LU0326950275.SGD","BK1191","LU0501845795.SGD","LU1008478684.HKD","LU1152091168.USD","LU1226287529.USD","IE00B543WZ88.USD","KURE","LU1807302812.USD","IE00B5MMRT66.SGD","LU1960683339.HKD","LU1328277881.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654274810","title":"CSPC Pharma's Depression Drug Meets Primary Endpoint in Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2654274810","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654274810?lang=en_us&edition=fundamental","pubTime":"2026-07-28 11:02","pubTimestamp":1785207730,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical  said its Phase 3 clinical trial of Ammoxetine Hydrochloride Enteric-coated Tablets met its primary endpoint in patients with depression, according to a Monday filing with the Hong Kong bourse.The trial showed the drug significantly improved Montgomery-sberg Depression Rating Scale  scores after eight weeks of treatment compared with placebo and was numerically superior to the active control.HA1406 also demonstrated favorable trends across multiple secondary endpoints and a good safety profile, the company said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B5MMRT66.SGD","LU1328277881.USD","LU0501845795.SGD","LU0315179316.USD","IE00BZ08YT58.USD","LU1813983027.USD","IE00B031HY20.USD","LU1152091754.HKD","BK1521","HK0000165453.HKD","IE00B543WZ88.USD","LU1226287792.SGD","LU0326950275.SGD","LU1226288253.USD","LU1807302812.USD","LU1226287529.USD","IE0008368742.USD","LU2039709279.SGD","IE00BZ08YS42.EUR","IE0008369823.USD","LU1993786604.SGD","LU1226288170.HKD","LU1152091168.USD","SG9999004220.SGD","LU0880133367.SGD","01093","LU1008478684.HKD","LU1951186391.HKD","LU1226287875.USD","BK1515","LU0140636845.USD","LU0072913022.USD","LU1960683339.HKD","BK1191","KURE","LU0067412154.USD","LU0314109678.HKD","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654027898","title":"Akeso Doses First Patient in Phase Ib/II NSCLC Trial of HER3 ADC Ak138d1 with Ivonescimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2654027898","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654027898?lang=en_us&edition=fundamental","pubTime":"2026-07-28 10:36","pubTimestamp":1785206161,"startTime":"0","endTime":"0","summary":"Akeso doses first patient in Phase Ib/II NSCLC trial of HER3 ADC AK138D1 with ivonescimabAkeso dosed the first patient in a Phase Ib/II study of its HER3 ADC AK138D1, alone or with ivonescimab, in adv","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nNDL5VnSD7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B5MMRT66.SGD","LU0348735423.USD","LU2778985437.USD","LU0561508036.HKD","LU2488822045.USD","LU0348825331.USD","LU0417516571.SGD","LU2399975544.HKD","LU1961090484.USD","LU2476274720.SGD","LU0634319403.HKD","LU0417516738.SGD","LU0540923850.HKD","LU0417516902.SGD","LU1720050803.USD","LU0348827113.USD","BK1161","09926","IE00BPRC5H50.USD","LU0348767384.USD","LU2476274308.USD","IE00B543WZ88.USD","LU1794554557.SGD","LU0348766576.USD","LU0348783233.USD","LU0348784397.USD","BK1574","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654869027","title":"CSPC Pharma's Sirolimus Drug Application Accepted in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2654869027","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654869027?lang=en_us&edition=fundamental","pubTime":"2026-07-28 10:34","pubTimestamp":1785206054,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical  said China's National Medical Products Administration accepted the new drug application for its independently developed Sirolimus for Injection, according to a Monday filing with the Hong Kong bourse.The application seeks approval for the treatment of unresectable locally advanced or metastatic malignant perivascular epithelioid cell tumor .","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1521","IE00BZ08YR35.GBP","KURE","LU1152091754.HKD","LU1008478684.HKD","LU1226287529.USD","LU1993786604.SGD","SG9999004220.SGD","LU1226287792.SGD","LU1226288253.USD","IE00B5MMRT66.SGD","IE00BZ08YS42.EUR","LU1807302812.USD","IE0008368742.USD","LU0072913022.USD","LU1226287875.USD","LU1951186391.HKD","LU2039709279.SGD","LU1813983027.USD","LU0315179316.USD","LU0140636845.USD","LU0880133367.SGD","LU1960683339.HKD","LU0314109678.HKD","LU1226288170.HKD","LU0501845795.SGD","LU1152091168.USD","IE00BZ08YT58.USD","IE00B031HY20.USD","LU0067412154.USD","LU0326950275.SGD","01093","HK0000165453.HKD","LU1328277881.USD","IE00B543WZ88.USD","IE0008369823.USD","BK1515","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179520655","title":"Hong Kong Stock Market Preview: Disease Prevention 15th Five-Year Plan Issued, SK Hynix Breaches IPO Price on Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1179520655","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179520655?lang=en_us&edition=fundamental","pubTime":"2026-07-28 07:44","pubTimestamp":1785195867,"startTime":"0","endTime":"0","summary":"Seven government departments have issued the \"15th Five-Year Plan for Disease Prevention and Control.\" The plan prioritizes the prevention and control of major infectious diseases, adopting a...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKHZ","BK1161","SG9999001051.SGD","LU1226288170.HKD","EDZ","SKHU","BK1227","SGXZ90724238.SGD","LU1813983027.USD","REDS","LU2039709279.SGD","KURE","LU1152091168.USD","LU1152091754.HKD","01093","IE00BZ08YS42.EUR","HK0000165453.HKD","BK4588","SG9999004220.SGD","BK1574","FRHC","09971","IPOS","BK1147","IE00B5MMRT66.SGD","09858","BK1212","LU0315179316.USD","LU1226287875.USD","RAM","LU0880133367.SGD","IE00BZ08YR35.GBP","IE0008369823.USD","SK","KCAI","BK1237","03958","09969","BK1587","LU1807302812.USD","LU1226287792.SGD","DRAL","LU1951186391.HKD","LU0501845795.SGD","BK4141","BK1544","LU1993786604.SGD","LU1226288253.USD","BK1191","KCE","06181","LU1008478684.HKD","IE0008368742.USD","SKHX","07709","HYNX","LU0067412154.USD","SKHYV","SKHY","IE00BZ08YT58.USD","LU1328277881.USD","SKUU","VXUS","LU0072913022.USD","BK4127","SKDD","LU0140636845.USD","LU0326950275.SGD","EEMO","BK1521","LU0314109678.HKD","BK1163","BK4585","BK1515","BK1564","LU1960683339.HKD","IE00B543WZ88.USD","LU1226287529.USD","IE00B031HY20.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654043367","title":"Cspc Pharmaceutical Says Phase III Trial of Ha1406 Meets Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2654043367","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654043367?lang=en_us&edition=fundamental","pubTime":"2026-07-27 21:20","pubTimestamp":1785158438,"startTime":"0","endTime":"0","summary":"BRIEF-Cspc Pharmaceutical Says Phase III Trial Of Ha1406 Meets Primary EndpointJuly 27 (Reuters)-CSPC Pharmaceutical Group Ltd1093.HK:PHASE III TRIAL OF HA1406 FOR DEPRESSION MEETS PRIMARY ENDPOINT WITH STATISTICAL SIGNIFICANCEFurther company coverage:1093.HK","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nFWN43T198:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1960683339.HKD","SG9999004220.SGD","LU0314109678.HKD","BK1191","LU1226287875.USD","LU1226288170.HKD","LU1951186391.HKD","LU0880133367.SGD","LU1226287792.SGD","LU0140636845.USD","BK1515","IE00BZ08YS42.EUR","HK0000165453.HKD","IE0008368742.USD","IE00B031HY20.USD","LU1152091754.HKD","KURE","LU0315179316.USD","IE00BZ08YT58.USD","BK1521","LU1328277881.USD","01093","LU1807302812.USD","LU2039709279.SGD","LU1226288253.USD","LU0326950275.SGD","IE0008369823.USD","IE00B543WZ88.USD","LU0067412154.USD","LU1152091168.USD","LU0501845795.SGD","LU1813983027.USD","LU1008478684.HKD","LU0072913022.USD","IE00BZ08YR35.GBP","LU1993786604.SGD","LU1226287529.USD","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125624783","title":"CSPC PHARMA's Injectable Sirolimus (Albumin-Bound) New Drug Application Accepted by China's NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=1125624783","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125624783?lang=en_us&edition=fundamental","pubTime":"2026-07-27 21:08","pubTimestamp":1785157686,"startTime":"0","endTime":"0","summary":"CSPC PHARMA (01093) has announced that its independently developed injectable sirolimus (albumin-bound) has had its marketing application accepted by the National Medical Products Administration...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1521","IE00BZ08YR35.GBP","KURE","LU1152091754.HKD","LU1008478684.HKD","LU1226287529.USD","LU1993786604.SGD","SG9999004220.SGD","LU1226287792.SGD","LU1226288253.USD","IE00B5MMRT66.SGD","IE00BZ08YS42.EUR","LU1807302812.USD","IE0008368742.USD","LU0072913022.USD","LU1226287875.USD","LU1951186391.HKD","LU2039709279.SGD","LU1813983027.USD","LU0315179316.USD","LU0140636845.USD","LU0880133367.SGD","IPOS","LU1960683339.HKD","LU0314109678.HKD","LU1226288170.HKD","LU0501845795.SGD","LU1152091168.USD","IE00BZ08YT58.USD","IE00B031HY20.USD","LU0067412154.USD","LU0326950275.SGD","01093","HK0000165453.HKD","LU1328277881.USD","IE00B543WZ88.USD","IE0008369823.USD","BK1515","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654048542","title":"CSPC Says China NMPA Accepts Sirolimus Albumin-bound Injection Filing, Grants Priority Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2654048542","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654048542?lang=en_us&edition=fundamental","pubTime":"2026-07-27 20:58","pubTimestamp":1785157084,"startTime":"0","endTime":"0","summary":"CSPC says China NMPA accepts sirolimus albumin-bound injection filing, grants priority reviewCSPC Pharmaceutical said China’s NMPA accepted its marketing application for albumin-bound sirolimus inject","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nNDL2j2LJ2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1226287792.SGD","LU1807302812.USD","BK1191","IE00BZ08YS42.EUR","LU1960683339.HKD","LU1226288170.HKD","01093","IE0008368742.USD","LU0067412154.USD","KURE","LU0140636845.USD","LU0501845795.SGD","LU1226287875.USD","IE00B031HY20.USD","LU1152091754.HKD","LU1226288253.USD","IE00B543WZ88.USD","IE00BZ08YR35.GBP","LU2039709279.SGD","BK1515","LU0072913022.USD","IE00B5MMRT66.SGD","LU1008478684.HKD","LU1152091168.USD","SG9999004220.SGD","LU0314109678.HKD","HK0000165453.HKD","BK1521","LU1226287529.USD","LU1993786604.SGD","IE0008369823.USD","LU0326950275.SGD","LU1951186391.HKD","LU1328277881.USD","LU0315179316.USD","LU1813983027.USD","IE00BZ08YT58.USD","LU0880133367.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654510048","title":"CSPC Pharmaceutical - Nmpa Accepts New Drug Application for Sirolimus for Injection (Albumin-Bound)","url":"https://stock-news.laohu8.com/highlight/detail?id=2654510048","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654510048?lang=en_us&edition=fundamental","pubTime":"2026-07-27 20:58","pubTimestamp":1785157082,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nFWN43T13U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE0008369823.USD","LU1152091754.HKD","LU1226287875.USD","IE00B031HY20.USD","KURE","LU1008478684.HKD","LU1152091168.USD","IE00BZ08YS42.EUR","LU1951186391.HKD","SG9999004220.SGD","LU0072913022.USD","LU1960683339.HKD","LU0501845795.SGD","LU1813983027.USD","LU1993786604.SGD","LU0315179316.USD","HK0000165453.HKD","BK1191","LU0880133367.SGD","IE00BZ08YR35.GBP","LU1226287792.SGD","LU1807302812.USD","IE00BZ08YT58.USD","BK1515","LU1226288253.USD","LU0314109678.HKD","LU1226288170.HKD","LU2039709279.SGD","LU1226287529.USD","LU1328277881.USD","IE00B5MMRT66.SGD","01093","LU0067412154.USD","IE0008368742.USD","IE00B543WZ88.USD","BK1521","LU0140636845.USD","LU0326950275.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654483280","title":"CSPC Pharmaceutical - Phase Iii Trial of Ha1406 for Depression Meets Primary Endpoint with Statistical Significance","url":"https://stock-news.laohu8.com/highlight/detail?id=2654483280","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654483280?lang=en_us&edition=fundamental","pubTime":"2026-07-27 20:55","pubTimestamp":1785156938,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nFWN43T198:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0326950275.SGD","LU1951186391.HKD","LU0072913022.USD","IE00B5MMRT66.SGD","HK0000165453.HKD","LU1152091168.USD","IE00BZ08YR35.GBP","BK1521","IE0008369823.USD","LU1813983027.USD","BK1515","SG9999004220.SGD","LU1226288253.USD","LU0501845795.SGD","LU1807302812.USD","IE00BZ08YT58.USD","IE0008368742.USD","LU1226287529.USD","LU0880133367.SGD","LU1226288170.HKD","IE00B543WZ88.USD","LU1226287875.USD","LU0314109678.HKD","LU1328277881.USD","LU1993786604.SGD","LU1008478684.HKD","IE00BZ08YS42.EUR","LU1960683339.HKD","BK1191","KURE","LU1226287792.SGD","LU1152091754.HKD","LU0140636845.USD","01093","LU2039709279.SGD","IE00B031HY20.USD","LU0315179316.USD","LU0067412154.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118082072","title":"CSPC PHARMA (01093) Issues Positive Profit Alert, Expects Significant Interim Net Profit Growth to Around RMB 5.9-6.2 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1118082072","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118082072?lang=en_us&edition=fundamental","pubTime":"2026-07-27 17:43","pubTimestamp":1785145424,"startTime":"0","endTime":"0","summary":"CSPC PHARMA (01093) has released a positive profit alert, announcing that the group expects its consolidated net profit attributable to shareholders for the six months ending June 30, 2026 (the...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0501845795.SGD","IE0008368742.USD","LU0315179316.USD","IE00BZ08YS42.EUR","IE00B543WZ88.USD","LU0314109678.HKD","BK1521","LU0140636845.USD","01093","LU1960683339.HKD","LU0880133367.SGD","SG9999004220.SGD","LU1226287792.SGD","LU0326950275.SGD","IE00BZ08YT58.USD","LU1152091168.USD","IE0008369823.USD","LU1951186391.HKD","LU1813983027.USD","IE00B5MMRT66.SGD","LU1226288170.HKD","LU1993786604.SGD","BK1515","LU1226287529.USD","LU0072913022.USD","LU0067412154.USD","LU1226287875.USD","LU1152091754.HKD","LU1328277881.USD","LU1008478684.HKD","BK1191","LU1226288253.USD","LU1807302812.USD","IE00B031HY20.USD","LU2039709279.SGD","IE00BZ08YR35.GBP","KURE","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":200,"code":"91000000","status":"200"}]}}